Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. - Wikidata - awgldk - TriplyDB

Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.

Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.

http://www.wikidata.org/entity/Q40022137

about

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer.Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.In Vivo Chemoprotective Activity of Bovine Dialyzable Leukocyte Extract in Mouse Bone Marrow Cells against Damage Induced by 5-Fluorouracil.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study.S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature.Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.ABCC11/MRP8 Expression in the Gastrointestinal Tract and a Novel Role for Pepsinogen Secretion.Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect.Efficacy of S-1 in colorectal cancer.Corneal limbal stem cell deficiency associated with the anticancer drug S-1.Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer Abnormalities in the meibomian glands in patients with oral administration of anticancer combination drug-capsule TS-1(®): a case report.Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma.S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma.A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).Current Development of Anti-Cancer Drug S-1.Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE.Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.S-1 as a core anticancer fluoropyrimidine agent.Metastatic gastric cancer treatment: a little slow but worthy progress.Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.

P2860

Q26786174-1BF278D2-12E3-42F1-A96D-717CBB9D8238 Q33399212-293D60EA-F77D-432F-B906-D247A3EB4945 Q33413701-1F30F3D3-27FE-4AFC-936A-043E1D817064 Q33416158-5806B2B6-6743-48FB-8D21-CAC364988811 Q33416894-E82AF8B7-394C-47EE-B14C-0A66844F1E2C Q33417107-ABE9BA70-CA0D-45DB-B1AC-FE2B925CF451 Q33428545-E9D9E3E9-53B8-41B1-ACC0-597207A6CA1B Q33432319-F5495266-1D93-46B1-9382-28A232DA4FC4 Q33433129-D7A8BC6F-23E2-4B48-B33F-24938C7CE33F Q33435747-2B8E8E84-2908-4D6E-8F50-D5B522097709 Q33436476-4345311A-9522-4B0A-B477-99704B4F2C83 Q33441277-9101CDA4-AE13-4433-82C8-77AE6831DF53 Q33573019-47F3A2CE-4EC7-4611-8EC5-159F00A3A7DA Q33643492-64A62715-393F-4B98-9F2C-859ADAE24998 Q33788372-3D89A945-C94E-44E5-9EEF-1D1DB2F509C2 Q33914210-B8DE1CC5-E872-4763-83E5-940F1AFE48D6 Q34062522-B695F9AE-580D-4C78-BF4D-8EE2D6162EEF Q34184465-45E3BAF7-911B-4B47-9DAF-9DB471261F27 Q34372789-6834AF54-7D20-40BE-A31C-405C881E9728 Q34429445-54309FBC-F8B3-4D85-8258-C644B9A5C445 Q35223435-8E56478B-3920-4513-AF0F-E1DB71E9BC1D Q35768446-C9417987-ED3D-4A12-8AA5-2E39FF971CF3 Q35820551-43CB1565-CDBA-4C13-831D-D6BA1B808EA7 Q36057115-0916CB06-09B7-4E95-8F8D-FD7E18F4E8A2 Q36076084-B235A687-0BE5-4DF5-96C0-3D1B7D23968A Q36194219-9EA1FFE8-FE28-404C-9319-E05D043F3801 Q36195618-874B0F4F-2319-43FF-882A-57B35A4E52C3 Q36195933-AED4DCE5-B3D0-410B-B553-6EBA2D8E3EFD Q36403236-90DB7866-FE3E-4D48-9E2B-193DAF52752B Q36795363-20B3A4C7-A8BF-48CF-91F7-FD281BA6D0A6 Q37491365-58825C7A-766A-4ED5-923D-09029D935B8C Q37543342-04170B90-2E33-4E41-88D1-03C408EB3FFE Q37657671-8658A6CF-2908-456D-97EE-C4323D8963EE Q37728873-367E759A-1E5A-4EC2-89F0-A6F158C0F4A3 Q37780473-AB4A120C-67C6-4848-9B93-01FB1211D070 Q37974935-ADF55900-378C-4A37-96A9-7C3FEFE4316B Q38075499-E96F303C-A1B4-4539-AC87-6B76C8488151 Q38343383-4B7B8636-BE2C-4D01-9383-1642C522961D Q38473718-0D16AAA5-4D56-481B-BC41-E5D52FEB1511 Q38551668-B4A2CBDA-701D-4104-B22C-4E513CD8FCB6

P2860

Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.

http://www.wikidata.org/entity/Q40022137

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Development history and concep ...... usefulness and future vistas.

@en

type

label

Development history and concep ...... usefulness and future vistas.

@en

prefLabel

Development history and concep ...... usefulness and future vistas.

@en

P1433

Q40022137-83A7B163-CC86-46BF-A6DA-C7258051C322

P1476

Q40022137-8DA5B450-464B-4AE2-9EC8-A1B4FDD730A5

P2093

Q40022137-F72D139C-8B04-4887-91C6-40A795157593

P2860

Q40022137-057C1016-EC08-4B74-8489-BB161E12697D

Q40022137-1378EB0D-710C-439B-978F-153EF6F2C32F

Q40022137-16CDF999-525B-42BE-9D36-25DE4ADC77B8

Q40022137-171D7EBB-1E6B-4DD6-B22A-00178B464032

Q40022137-17B6CD83-8183-436D-8AFB-9E2E3867953B

Q40022137-278BC7B2-6045-4857-855C-261AD236A0E0

Q40022137-2C80C8CB-4423-4635-AFEA-C2EFFBCAA98C

Q40022137-30800878-8446-477E-BDC2-E554F8A2F611

Q40022137-38FCC4BB-3A9E-435D-B5A2-8265A9B3388C

Q40022137-3BA35BFF-FCAE-49C4-9F5D-8C8BECF88EF8

P304

Q40022137-5C0D06EF-E302-4B62-9602-7EFD3A247B05

P31

Q40022137-A1B8366F-2936-40F9-B892-C0592300C758

P356

Q40022137-1C41C809-C403-494E-A98D-41B854A2A973

P433

Q40022137-A147070F-25D8-4F8B-8199-A9CA1093D27C

P478

Q40022137-1D757A1A-4141-4CAE-B5F9-15817E33AE40

P577

Q40022137-46AB576C-BD78-4C85-8EA6-A5D4AF09F898

P5875

Q40022137-A83F4627-67D5-4378-AC37-58D6FC465FBE

P698

Q40022137-68DEC397-1E32-4792-8746-6A32FC0D8A7C

P932

Q40022137-4417DB7C-72F1-4F71-A573-5ED86CB5CF0E

P356

P1433

Japanese Journal of Clinical Oncology

P1476

Development history and concep ...... usefulness and future vistas.

@en

P2093

Tetsuhiko Shirasaka

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

[Late phase II study of S-1 in patients with advanced head and neck cancer].

[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].

[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.

Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer.

Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.

Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.

P304

2-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYN127

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23566985

http://www.w3.org/2001/XMLSchema#string

P698

19052037

http://www.w3.org/2001/XMLSchema#string

P932

2639406

http://www.w3.org/2001/XMLSchema#string